{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:32:14Z","timestamp":1782253934671,"version":"3.54.5"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4109,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Hepatic fibrosis and cirrhosis are possible consequences of corticosteroid-treated autoimmune hepatitis. Our aims were to determine the frequency of progressive fibrosis and the factors associated with this progression. Two hundred seventy-seven liver tissue specimens that had been obtained from 73 patients were interpreted in batch under code by a single pathologist. Fibrosis scores and histological activity indices were determined using the Ishak scoring system, and worsening fibrosis scores were correlated with clinical features, laboratory findings, and treatment responses. Fibrosis scores increased (2.3 \u00b1 0.4 points to 4.2 \u00b1 0.4 points; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .0001) in 18 patients (25%) during 79 \u00b1 13 months. Only five patients (7%) developed cirrhosis, and 55 patients (75%) had stable (16 patients) or decreased (39 patients) fibrosis scores. Human leukocyte antigen (HLA) DR3\/DR4 occurred more frequently in patients with progressive fibrosis than others (23% vs. 2%; <jats:italic toggle=\"yes\">P<\/jats:italic> = .03). Patients with progressive fibrosis had higher histological activity indices at last follow-up than patients with stable or reduced fibrosis (3.2 \u00b1 0.7 vs. 1.7 \u00b1 0.2; <jats:italic toggle=\"yes\">P<\/jats:italic> = .01), and these indices worsened more commonly during therapy (17% vs. 2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .04). Relapse, treatment failure, and incomplete response did not affect progression of fibrosis. <jats:underline>In conclusion<\/jats:underline>, fibrosis progresses in only a minority of patients during corticosteroid therapy. Progression is associated with HLA DR3\/DR4 and worsening histological activity. Exacerbations or persistence of disease activity does not increase disease progression after treatment has been instituted. (Hepatology 2004;39:1631-1638.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20235","type":"journal-article","created":{"date-parts":[[2004,5,27]],"date-time":"2004-05-27T20:02:07Z","timestamp":1085688127000},"page":"1631-1638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":110,"title":["Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis\u2020"],"prefix":"10.1097","volume":"39","author":[{"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herschel A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20241201","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis.","volume":"36","author":"Czaja","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-22-20241201","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-2002-35706","article-title":"Treatment of autoimmune hepatitis.","volume":"22","author":"Czaja","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R3-22-20241201","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"R4-22-20241201","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0016-5085(84)90186-0","article-title":"Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis.","volume":"87","author":"Davis","year":"1984","journal-title":"Gastroenterology"},{"key":"R5-22-20241201","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"R6-22-20241201","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1089-3261(02)00028-4","article-title":"Treatment strategies in autoimmune hepatitis.","volume":"6","author":"Czaja","year":"2002","journal-title":"Clin Liver Dis"},{"key":"R7-22-20241201","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/hep.1840110621","article-title":"Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.","volume":"11","author":"Czaja","year":"1990","journal-title":"HEPATOLOGY"},{"key":"R8-22-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for long-term maintenance of remission in autoimmune hepatitis.","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"R9-22-20241201","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/hep.1840130415","article-title":"Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors.","volume":"13","author":"Donaldson","year":"1991","journal-title":"HEPATOLOGY"},{"key":"R10-22-20241201","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/0016-5085(93)90157-8","article-title":"Significance of HLA DR4 in type 1 autoimmune hepatitis.","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R11-22-20241201","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.510250211","article-title":"Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.","volume":"25","author":"Czaja","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R12-22-20241201","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","article-title":"Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis.","volume":"117","author":"Czaja","year":"1999","journal-title":"Gastroenterology"},{"key":"R13-22-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.510310110","article-title":"CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis.","volume":"31","author":"Agarwal","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R14-22-20241201","first-page":"1087","article-title":"Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.","volume":"20","author":"Soloway","year":"1975","journal-title":"Am J Dig Dis"},{"key":"R15-22-20241201","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(80)90135-3","article-title":"Observer variation in assessment of liver biopsies including analysis by kappa statistics.","volume":"79","author":"Theodossi","year":"1980","journal-title":"Gastroenterology"},{"key":"R16-22-20241201","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1053\/gast.2002.33367","article-title":"Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C.","volume":"122","author":"Arthur","year":"2002","journal-title":"Gastroenterology"},{"key":"R17-22-20241201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsies in patients with chronic hepatitis C.","volume":"20","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R18-22-20241201","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1478-3231.1999.tb00033.x","article-title":"Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection.","volume":"19","author":"Westin","year":"1999","journal-title":"Liver"},{"key":"R19-22-20241201","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hep.510310136","article-title":"Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.","volume":"31","author":"Brunt","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R20-22-20241201","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R21-22-20241201","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.510240515","article-title":"Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.","volume":"24","author":"Czaja","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R22-22-20241201","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1023\/A:1018809431189","article-title":"Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis.","volume":"42","author":"Czaja","year":"1997","journal-title":"Dig Dis Sci"},{"key":"R23-22-20241201","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/0016-5085(92)91518-9","article-title":"Frequency and significance of antibodies to liverkidney microsome type 1 in adults with chronic active hepatitis.","volume":"103","author":"Czaja","year":"1992","journal-title":"Gastroenterology"},{"key":"R24-22-20241201","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"R25-22-20241201","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/jhep.2002.32485","article-title":"Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.","volume":"35","author":"Czaja","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R26-22-20241201","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R27-22-20241201","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200102083440610","article-title":"Is liver fibrosis reversible?","volume":"344","author":"Bonis","year":"2001","journal-title":"N Engl J Med"},{"key":"R28-22-20241201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-8278(05)80005-4","article-title":"Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis.","volume":"18","author":"Schvarcz","year":"1993","journal-title":"J Hepatol"},{"key":"R29-22-20241201","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","article-title":"Reversibility of hepatic fibrosis in autoimmune hepatitis.","volume":"127","author":"Dufour","year":"1997","journal-title":"Ann Intern Med"},{"key":"R30-22-20241201","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00004836-200105000-00014","article-title":"Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.","volume":"32","author":"Cotler","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"R31-22-20241201","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJM199306243282508","article-title":"The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.","volume":"328","author":"Friedman","year":"1993","journal-title":"N Engl J Med"},{"key":"R32-22-20241201","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.","volume":"275","author":"Friedman","year":"2000","journal-title":"J Biol Chem"},{"key":"R33-22-20241201","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jlb.60.5.563","article-title":"Regulation of cytokine and cytokine receptor expression by glucocorticoids.","volume":"60","author":"Almawi","year":"1996","journal-title":"J Leukoc Biol"},{"key":"R34-22-20241201","first-page":"78","article-title":"Molecular mechanisms of glucocorticoid effects.","volume":"2","author":"Almawi","year":"2001","journal-title":"Mod Asp Immunobiol"},{"key":"R35-22-20241201","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.","volume":"102","author":"Iredale","year":"1998","journal-title":"J Clin Invest"},{"key":"R36-22-20241201","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1074\/jbc.M111490200","article-title":"Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis.","volume":"277","author":"Murphy","year":"2002","journal-title":"J Biol Chem"},{"key":"R37-22-20241201","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/gut.48.4.548","article-title":"Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors.","volume":"48","author":"Issa","year":"2001","journal-title":"Gut"},{"key":"R38-22-20241201","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1357-2725(98)00005-3","article-title":"Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter.","volume":"30","author":"Parrelli","year":"1998","journal-title":"Int J Biochem Cell Biol"},{"key":"R39-22-20241201","first-page":"4490","article-title":"Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone.","volume":"11","author":"Centrella","year":"1991","journal-title":"Mol Cell Biol"},{"key":"R40-22-20241201","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1572-0241.2002.05921.x","article-title":"Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.","volume":"97","author":"Czaja","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R41-22-20241201","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1572-0241.2001.03707.x","article-title":"Understanding the pathogenesis of autoimmune hepatitis.","volume":"96","author":"Czaja","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R42-22-20241201","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1053\/gast.1997.v112.pm9178696","article-title":"Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis.","volume":"112","author":"Strettell","year":"1997","journal-title":"Gastroenterology"},{"key":"R43-22-20241201","first-page":"244","article-title":"Impact of liver biopsy size on the histological evaluation of chronic hepatitis: the smaller the sample, the milder the disease.","volume":"239-","author":"Colloredo","year":"2003","journal-title":"J Hepatol"},{"key":"R44-22-20241201","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C.","volume":"38","author":"Bedossa","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R45-22-20241201","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.hep.2003.10.010","article-title":"Liver biopsy size matters in chronic hepatitis: bigger is better.","volume":"38","author":"Scheuer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R46-22-20241201","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2559.1998.00413.x","article-title":"Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.","volume":"32","author":"Kaserer","year":"1998","journal-title":"Histopathology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20235","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:15:00Z","timestamp":1733055300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200406000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20235","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}